4/11
07:06 am
kprx
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study [Yahoo! Finance]
Low
Report
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study [Yahoo! Finance]
4/5
07:14 am
kprx
Kiora Pharmaceuticals to Present at Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Kiora Pharmaceuticals to Present at Upcoming Investor Conferences [Yahoo! Finance]
3/28
07:01 am
kprx
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting [Yahoo! Finance]
High
Report
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting [Yahoo! Finance]
3/27
08:08 am
kprx
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
Low
Report
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
3/25
09:05 am
kprx
Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases [Yahoo! Finance]
Medium
Report
Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases [Yahoo! Finance]
3/8
07:12 am
kprx
Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye [Yahoo! Finance]
Low
Report
Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye [Yahoo! Finance]
2/20
09:18 am
kprx
OcuSciences Welcomes Michael Patane, PhD, to its Board of Directors [Yahoo! Finance]
Low
Report
OcuSciences Welcomes Michael Patane, PhD, to its Board of Directors [Yahoo! Finance]
2/9
08:10 am
kprx
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) had its price target lowered by analysts at HC Wainwright from $3.50 to $2.00. They now have a "buy" rating on the stock.
Low
Report
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) had its price target lowered by analysts at HC Wainwright from $3.50 to $2.00. They now have a "buy" rating on the stock.